The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates
Name:
36131292.pdf
Size:
1.806Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Buhigas, C.Warren, A. Y.
Leung, W. K.
Whitaker, H. C.
Luxton, H. J.
Hawkins, S.
Kay, J.
Butler, A.
Xu, Y.
Woodcock, D. J.
Merson, S.
Frame, F. M.
Sahli, A.
Abascal, F.
Martincorena, I.
Bova, G. S.
Foster, C. S.
Campbell, P.
Maitland, N. J.
Neal, D. E.
Massie, C. E.
Lynch, A. G.
Eeles, R. A.
Cooper, C. S.
Wedge, David C
Brewer, D. S.
Affiliation
Norwich Medical School, University of East Anglia, Norwich, Norfolk, NR4 7TJ, UKIssue Date
2022
Metadata
Show full item recordAbstract
Background: Up to 80% of cases of prostate cancer present with multifocal independent tumour lesions leading to the concept of a field effect present in the normal prostate predisposing to cancer development. In the present study we applied Whole Genome DNA Sequencing (WGS) to a group of morphologically normal tissue (n = 51), including benign prostatic hyperplasia (BPH) and non-BPH samples, from men with and men without prostate cancer. We assess whether the observed genetic changes in morphologically normal tissue are linked to the development of cancer in the prostate. Results: Single nucleotide variants (P = 7.0 × 10-03, Wilcoxon rank sum test) and small insertions and deletions (indels, P = 8.7 × 10-06) were significantly higher in morphologically normal samples, including BPH, from men with prostate cancer compared to those without. The presence of subclonal expansions under selective pressure, supported by a high level of mutations, were significantly associated with samples from men with prostate cancer (P = 0.035, Fisher exact test). The clonal cell fraction of normal clones was always higher than the proportion of the prostate estimated as epithelial (P = 5.94 × 10-05, paired Wilcoxon signed rank test) which, along with analysis of primary fibroblasts prepared from BPH specimens, suggests a stromal origin. Constructed phylogenies revealed lineages associated with benign tissue that were completely distinct from adjacent tumour clones, but a common lineage between BPH and non-BPH morphologically normal tissues was often observed. Compared to tumours, normal samples have significantly less single nucleotide variants (P = 3.72 × 10-09, paired Wilcoxon signed rank test), have very few rearrangements and a complete lack of copy number alterations. Conclusions: Cells within regions of morphologically normal tissue (both BPH and non-BPH) can expand under selective pressure by mechanisms that are distinct from those occurring in adjacent cancer, but that are allied to the presence of cancer. Expansions, which are probably stromal in origin, are characterised by lack of recurrent driver mutations, by almost complete absence of structural variants/copy number alterations, and mutational processes similar to malignant tissue. Our findings have implications for treatment (focal therapy) and early detection approaches.Citation
Buhigas C, Warren AY, Leung WK, Whitaker HC, Luxton HJ, Hawkins S, et al. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates. Mol Cancer. 2022 Sep 22;21(1):183. PubMed PMID: 36131292. Pubmed Central PMCID: PMC9494848. Epub 2022/09/22. eng.Journal
Molecular CancerDOI
10.1186/s12943-022-01644-3PubMed ID
36131292Additional Links
https://dx.doi.org/10.1186/s12943-022-01644-3Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1186/s12943-022-01644-3
Scopus Count
Collections
Related articles
- Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.
- Authors: Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N, Massie CE, Kay J, Luxton HJ, Edwards S, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Corbishley C, Thomas S, Nik-Zainal S, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, Boutros PC, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N, ICGC Prostate Group, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC, Gnanapragasam V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton MR, Whitaker HC, McDermott U, Brewer DS, Neal DE
- Issue date: 2015 Apr
- Spatial architectures of somatic mutations in normal prostate, benign prostatic hyperplasia and coexisting prostate cancer.
- Authors: Chae J, Jung SH, Choi EJ, Kim JW, Kim NY, Moon SW, Lee JY, Chung YJ, Lee SH
- Issue date: 2024 Feb
- Organ-wide telomeric status in diseased and disease-free prostatic tissues.
- Authors: Heaphy CM, Fleet TM, Treat EG, Lee SJ, Smith AY, Davis MS, Griffith JK, Fischer EG, Bisoffi M
- Issue date: 2010 Sep 15
- Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
- Authors: White JA, Kaninjing ET, Adeniji KA, Jibrin P, Obafunwa JO, Ogo CN, Mohammed F, Popoola A, Fatiregun OA, Oluwole OP, Thorpe RJ Jr, Karanam B, Elhussin I, Ambs S, Tang W, Davis M, Polak P, Campbell MJ, Brignole KR, Rotimi SO, Dean-Colomb W, Odedina FT, Yates C
- Issue date: 2024 Apr
- Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis.
- Authors: Middleton LW, Shen Z, Varma S, Pollack AS, Gong X, Zhu S, Zhu C, Foley JW, Vennam S, Sweeney RT, Tu K, Biscocho J, Eminaga O, Nolley R, Tibshirani R, Brooks JD, West RB, Pollack JR
- Issue date: 2019 May 16